{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-109423","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.964850+00:00","generated_at":"2026-06-09T23:03:33.443322+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Eloxx receives Nasdaq delisting notice; trading suspended Oct 16, shares to OTC","bullets":["Nasdaq notified Eloxx on Oct 12, 2023 that it failed to regain compliance with $35M MVLS rule.","Trading of common stock (ELOX) suspended on Nasdaq effective Oct 16, 2023; will trade OTC under same symbol.","Company intends to request review by Nasdaq Listing Council, which stays delisting filing but not suspension.","Previously granted extensions expired Oct 9, 2023; stock has been below compliance threshold for over a year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-109423","json":"https://secwatch.observer/filing/0001104659-23-109423.json","markdown":"https://secwatch.observer/filing/0001104659-23-109423.md","text":"https://secwatch.observer/filing/0001104659-23-109423.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923109423/0001104659-23-109423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923109423/tm2328531d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:03:33.443322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fba316ca0c89bc461bf9030aef14d38cafe0bbef","claim":"Eloxx Pharmaceuticals, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"October 12, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), received a determination letter (the “Delisting Notification”) from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that Nasdaq will suspend trading in the Company’s common stock, par value $0.01 per share (the “Common Stock”), effective at the opening of trading on October 16, 2023, because the Company had not regained compliance with the Nasdaq Listing Rule 5550(b)(2) (the “Listing Rule”), which requires a listed company to have at least $3","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923109423/0001104659-23-109423-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"market value"},{"label":"Rules","value":"5550(b)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}